The Influence of Oral Contraceptives During Disuse

Rehabilitation Clinical Trial

Official title:

The Effects of Oral Contraceptive Use on Grip Strength and Neuromuscular Activation During Short-Term Immobilization of the Wrist/Hand

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06275048
• Other study ID #: STUDY00006302
• Status: Recruiting
• Phase: N/A
• Start date: January 26, 2024
• Est. completion date: May 2025

Study information

• Verified date: February 2024
• Source: University of Central Florida
• Contact: Matt S Stock, Ph.D.
• Phone: 407-823-0364
• Email: matt.stock[@]ucf.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Studies across various sports and physical activities have consistently shown that females incur more injuries compared to their male counterparts, but the underlying reasons for this disparity remain poorly understood. While differences in hormone levels between males and females have been speculated to play a role, very little rigorous research has been conducted to directly examine potential connections between sex hormones and injury risk. Specifically, females have been shown to be at greater risk for hand and wrist injuries. The higher injury incidence begins at puberty and persists across the lifespan, suggesting a link to hormonal factors. However, significant gaps remain in understanding the relationships between the menstrual cycle, exogenous hormones from birth control, and risk factors for sports-related injury in females. The purpose of this study is to examine changes in muscle strength and neuromuscular activation among females using monophasic oral contraceptives, females not using oral contraceptives, and males during one week of wrist/hand immobilization.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: May 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Right handed males and females
• Ages 18-35 years
• For females, consistent use of monophasic oral contraceptives for the previous 6 months OR having completely refrained from contraceptives for the previous 6 months.

Exclusion Criteria:

• Gender identity inconsistent with biological sex (due to the influence that drugs used for gender reassignment may have)
• Females that are amenorrheic (lack of menstruation for =3 consecutive cycles) or oligomenorrheic (menstrual cycle length =36 days)
• Menstrual cycle irregularities among females not using oral contraceptives (regularity defined as every 21 to 35 days and/or at least 5 periods in the last six months)
• Any contraceptive use other than monophasic oral contraceptives within the last 6 months
• Monophasic oral contraceptives that has been inconsistent over the previous 6 months
• Score of greater than 2/5 on question 9, or a score of greater than 1/5 on question 10 or 11 on the quick Disabilities of the Arm, Shoulder and Hand outcome measure indicating pain/discomfort of the upper extremities (shoulder, elbow, wrist, hand)
• Dominant hand is the left hand
• Body Mass Index less than 18.5 kg/m2 or greater than 29.9 kg/m2
• Current depression or anxiety
• History of musculoskeletal injury, pain, or surgery of the elbow, wrist, or hand
• Unwillingness to avoid upper-body exercise during Phase 1
• Unwillingness to avoid exercise and alcohol 24 hours prior to each testing visit.
• Neuromuscular disease (e.g., Multiple Sclerosis, amyotrophic lateral sclerosis, Parkinson's)
• Metabolic disease (e.g., diabetes, thyroid disorder, metabolic syndrome)
• Personal or family history of blood clots
• Trouble using or controlling muscles
• History of cancer
• History of stroke
• History of heart attack
• History of arthritis
• Allergy to rubbing alcohol
• Lack of transportation to and from the laboratory
• Current or planned pregnancy (within the next three months)
• Implant of any kind
• The use of medications that may increase the risk of blood clots (i.e., corticosteroids such as prednisone, testosterone and anabolic steroids, selective estrogen receptor modulators like tamoxifen, aromatase inhibitors including anastrozole, thalidomide and lenalidomide, erythropoiesis-stimulating agents such as epoetin alfa, antipsychotics like chlorpromazine, antidepressants including paroxetine, various cancer chemotherapies, immune modulating drugs, antivirals such as ritonavir, and tamoxifen).
• The use of creatine monohydrate and beta alanine supplementation within the previous 6 months.
• The use of any medication or supplement that could influence hormone levels within the previous 6 months.

Related Conditions & MeSH terms

• Menstrual Cycle
• Oral Contraceptives
• Physical Therapy
• Rehabilitation

Intervention

Other:
• Wrist/hand immobilization
Study participants will have their left wrist/hand immobilized with a splint for 7 days. The splint will be worn 24 hours per day.

Locations

Country	Name	City	State
United States	University of Central Florida	Orlando	Florida

Sponsors (1)

Lead Sponsor	Collaborator
University of Central Florida

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Grip Strength	Maximal force (N) will be measured during a grip strength test	Grip strength will be tested weekly for at least 3 weeks (i.e., baseline, post-immobilization, post 1 week recovery). Testing will continue every week following immobilization until grip strength has returned to baseline levels.
Secondary	Muscle activation	Surface electromyographic amplitude of hand and wrist muscles will be measured during the maximal grip tests.	Grip strength will be tested weekly for at least 3 weeks (i.e., baseline, post-immobilization, post 1 week recovery). Testing will continue every week following immobilization until grip strength has returned to baseline levels.